SNOA Sonoma Pharmaceuticals Inc. Quick Ratio

The price action of Sonoma Pharmaceuticals (SNOA) demonstrates the 2.31 coefficient. Sonoma Pharmaceuticals develops dermatological products while facing pricing pressure, patent threats, and complexities regarding insurance reimbursements. Current cash flow remains stable, but profits are limited due to promotion costs. Business resilience is supported by the supply of wound healing products to global clinics and pharmacy chains.

SNOA: Sonoma Pharmaceuticals, Inc. Intermediate Coverage Ratio 07/04/2022 - 11/01/2026

SNOA (Sonoma Pharmaceuticals): analytical breakdowns and indicator data

- market value and analyst target forecast:

Price Chart sonomapharma.com|SNOA - Consensus Target

- market capitalization data:

Market Capitalization Sonoma Pharma|SNOA - Enterprise Value

- balance sheet net asset value indicators:

Accounting Value per Share Sonoma Pharmaceuticals|SNOA - Accounting Value of Company|Market Value to Book Value Ratio sonomapharma.com|SNOA - Company Total Asset Base

- debt and liquidity data:

- earnings and valuation multiples information:

SNOA - Company Net Income

Analysis of all company metrics:Sonoma Pharmaceuticals

Manufactured product of Sonoma Pharmaceuticals

Investors assess the margin of safety for Sonoma Pharmaceuticals (SNOA) through its ability to immediately settle short-term liabilities without liquidating inventory. Technological leadership in developing antiseptic nano-formulas requires stable R&D funding. The absolute trend of quick liquidity demonstrates the ratio of cash and accounts receivable to current debts. High values confirm the asset's financial stability, eliminating the risk of bankruptcy during operational stagnation.

Key competitors